Skip to main content

Table 1 Patient and tumour characteristics (n=351)

From: High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients

Characteristics  
Median follow-up (months) 59.3 (16.5-82.6)
Gland volume at implant (cc)  
   mean 41
   median 39 (16–107)
Age at treatment (years)  
   mean 67.7
   median 68.4 (44.1-82.2)
Pre-treatment PSA (ng/ml)  
   mean 7.1
   median 6.4 (2.0-34.1)
  n (%)
Stage  
   T1b-c 129 (36.7%)
   T2a 113 (32.1%)
   T2b 55 (15.6%)
   T2c 53 (15.0%)
   T3a 1 (0.2%)
Gleason score  
   ≤ 6 281 (80.0%)
   7 62 (17.6%)
   > 7 8 (2.2%)
Pre-treatment PSA (ng/ml)  
   ≤ 10 324 (92.3%)
   11-20 23 (6.5%)
   > 20 4 (1.1%)
Age at treatment (years)  
   < 60 51 (14.5%)
   60-69 169 (48.1%)
   ≥ 70 131 (37.3%)
Androgen deprivation therapy 70 (19.9%)
Risk group  
   Low 196 (55.8%)
   Intermediate 81 (23.0%)
   High 74 (21.0%)